Lakefront Biotherapeutics has appointed Dr. Mehdi Shahidi as a Non-Executive Independent Director to its Board, effective November 2, 2026. Dr. Shahidi brings over 20 years of experience in drug development, regulatory success, and leadership in global pharmaceutical R&D. His expertise is expected to strengthen Lakefront's strategic guidance as the company advances its clinical-stage portfolio, including its lead candidate gamgertamig for autoimmune diseases. This appointment follows the resignation of Dr. Paulo Fontoura, who left to lead R&D at Sanofi SA.
Lakefront Biotherapeutics board appointment provides context for health sector data. For readers following health stocks, here is Pluang's market snapshot as of Nov 03, 2026 04:11 WIB: Out of 150 priced US health stocks, 48 rose and 100 fell. Notable movers include TXG at USD 61.51 with a -12.27% change and a typical hold time of 92 days, SLS at USD 8.56 down 11.48%, and DFTX at USD 32.32 down 11.04%.
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
Exosens disclosed its monthly update on the total number of shares and voting rights in its share capital as of October 31, 2026. The company has 50,936,749 shares outstanding, with 59,162,039 exercisable voting rights after deducting treasury shares...
Exosens has released its monthly update on the total number of shares and voting rights composing its capital as of October 31, 2026. The company reports 50,936,749 total shares and 59,425,768 theoretical voting rights, with 59,162,039 exercisable vo...
Recursion Pharmaceuticals announced positive Phase 2 results for REC-4881, an oral MEK1/2 inhibitor, in treating familial adenomatous polyposis (FAP). The TUPELO trial showed a 47% median reduction in total polyp burden after 12 weeks of treatment, w...
Vornado Realty Trust reported a net loss of $47.1 million for Q3 2026, a decline from net income of $11.6 million in the prior year period, primarily due to a large gain in 2025 related to a master lease. However, funds from operations (FFO) increase...
